Bone composition: relationship to bone fragility and antiosteoporotic drug effects
- PMID: 24501681
- PMCID: PMC3909232
- DOI: 10.1038/bonekey.2013.181
Bone composition: relationship to bone fragility and antiosteoporotic drug effects
Erratum in
-
Erratum: Bone composition: relationship to bone fragility and antiosteoporotic drug effects.Bonekey Rep. 2015 Jun 3;4:710. doi: 10.1038/bonekey.2015.79. eCollection 2015. Bonekey Rep. 2015. PMID: 26069736 Free PMC article.
Abstract
The composition of a bone can be described in terms of the mineral phase, hydroxyapatite, the organic phase, which consists of collagen type I, noncollagenous proteins, other components and water. The relative proportions of these various components vary with age, site, gender, disease and treatment. Any drug therapy could change the composition of a bone. This review, however, will only address those pharmaceuticals used to treat or prevent diseases of bone: fragility fractures in particular, and the way they can alter the composition. As bone is a heterogeneous tissue, its composition must be discussed in terms of the chemical makeup, properties of its chemical constituents and their distributions in the ever-changing bone matrix. Emphasis, in this review, is placed on changes in composition as a function of age and various diseases of bone, particularly osteoporosis. It is suggested that while some of the antiosteoporotic drugs can and do modify composition, their positive effects on bone strength may be balanced by negative ones.
Conflict of interest statement
Dr Boskey's work on FTIRI and osteoporosis has been funded by the NIH. The author declares no conflict of interest.
Figures
References
-
- Boskey A. Mineralization of bones and teeth. Elements Mag 2007;3:385–392.
-
- Young MF. Bone matrix proteins: their function, regulation, and relationship to osteoporosis. Osteoporos Int 2003;14:S35–S42. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials